The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit discusses what she learned at the inaugural AACR Drug Discovery ...
The Pancreatic Cancer Action Network responds to FDA approval of Rasonque™ (daraxonrasib) for patients with previously ...
Every so often, there is a breakthrough in cancer research that changes what people believe is possible. For pancreatic cancer, that moment is now. The recent news about a new oral therapy, ...
Dr. Jill P. Smith is a clinician scientist and professor of medicine at Georgetown University and a member of the Lombardi Comprehensive Cancer Center. She also is a staff physician in ...
Daraxonrasib is poised to become the new standard of care for previously treated metastatic pancreatic cancer after detailed results from a Phase III clinical trial were released at the American ...
For the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma, more than 90% of tumors are thought to have a KRAS mutation. For decades, these mutations were considered “undruggable, ...
American Cancer Society’s Cancer Facts & Figures 2023, released today, reports that the five-year survival rate for pancreatic cancer is now 12%, an increase of one percentage point from last year.
The types of cancer people are getting and dying from most may be changing in the next 20 years, according to a new study. Published today in JAMA Network Open, PanCAN and our research partners at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results